Portal de investigação
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Autores da FMUP
Participantes de fora da FMUP
- Antic D
- Milic N
- Chatzikonstantinou T
- Scarfò L
- Otasevic V
- Rajovic N
- Allsup D
- Alonso Cabrero A
- Andres M
- Baile Gonzales M
- Capasso A
- Collado R
- Cordoba R
- Cuéllar-García C
- Correa JG
- De Paoli L
- De Paolis MR
- Del Poeta G
- Dimou M
- Doubek M
- Efstathopoulou M
- El-Ashwah S
- Enrico A
- Espinet B
- Farina L
- Ferrari A
- Foglietta M
- Lopez-Garcia A
- García-Marco JA
- García-Serra R
- Gentile M
- Gimeno E
- da Silva MG
- Gutwein O
- Hakobyan YK
- Herishanu Y
- Hernández-Rivas JÁ
- Herold T
- Itchaki G
- Jaksic O
- Janssens A
- Kalashnikova OB
- Kalicinska E
- Kater AP
- Kersting S
- Koren-Michowitz M
- Labrador J
- Lad D
- Laurenti L
- Fresa A
- Levin MD
- Mayor Bastida C
- Malerba L
- Marasca R
- Marchetti M
- Marquet J
- Mihaljevic B
- Milosevic I
- Mirás F
- Morawska M
- Motta M
- Munir T
- Murru R
- Olivieri J
- Pavlovsky MA
- Piskunova I
- Popov VM
- Quaglia FM
- Quaresmini G
- Reda G
- Rigolin GM
- Shrestha A
- Šimkovic M
- Smirnova S
- Špacek M
- Sportoletti P
- Stanca O
- Stavroyianni N
- Te Raa D
- Tomic K
- Tonino S
- Trentin L
- Van Der Spek E
- van Gelder M
- Varettoni M
- Visentin A
- Vitale C
- Vukovic V
- Wasik-Szczepanek E
- Wróbel T
- Segundo LYS
- Yassin M
- Coscia M
- Rambaldi A
- Montserrat E
- Foà R
- Cuneo A
- Carrier M
- Ghia P
- Stamatopoulos K
Unidades de investigação
Abstract
BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. METHODS: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. RESULTS: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007?1.038 and OR = 1.025, 95%CI 1.001?1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061?0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017-1.109 and OR = 2.438, 95%CI 1.023-5.813, respectively). CONCLUSIONS: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.
© 2022. The Author(s).
Dados da publicação
- ISSN/ISSNe:
- 1756-8722, 1756-8722
- Tipo:
- Article
- Páginas:
- 116-116
Journal of Hematology and Oncology BioMed Central Ltd.
Documentos
- Não há documentos
Filiações
Keywords
- Age; Anticoagulation therapy; Bleeding; CLL; COVID-19; D-dimer; LMWH; Thromboprophylaxis; Thrombosis
Proyectos asociados
A ameaça da não-vacinação na sociedade digital e da desinformação
Investigador Principal: Rui Manuel Lopes Nunes
Estudo Clínico Académico (desinformação) . 2020
Autonomia ou beneficência - que princípio prevalece entre os prestadores de cuidados de saúde portugueses?
Investigador Principal: Rui Manuel Lopes Nunes
Estudo Clínico Académico . 2020
Spiritual advocacy in palliative care: A moral agency approach
Investigador Principal: Rui Manuel Lopes Nunes
Estudo Clínico Académico . 2021
Ameaça aos princípios bioéticos na pratica médica no Brasil: Duas Décadas dos Processos ético-profissionais (1988-2008)
Investigador Principal: Rui Manuel Lopes Nunes
Estudo Clínico Académico . 2019
Citar a publicação
Antic D,Milic N,Chatzikonstantinou T,Scarfò L,Otasevic V,Rajovic N,Allsup D,Alonso A,Andres M,Baile M,Capasso A,Collado R,Cordoba R,Cuéllar C,Correa JG,De Paoli L,De Paolis MR,Del Poeta G,Dimou M,Doubek M,Efstathopoulou M,El S,Enrico A,Espinet B,Farina L,Ferrari A,Foglietta M,Lopez A,García JA,García R,Gentile M,Gimeno E,da MG,Gutwein O,Hakobyan YK,Herishanu Y,Hernández JÁ,Herold T,Itchaki G,Jaksic O,Janssens A,Kalashnikova OB,Kalicinska E,Kater AP,Kersting S,Koren M,Labrador J,Lad D,Laurenti L,Fresa A,Levin MD,Mayor C,Malerba L,Marasca R,Marchetti M,Marquet J,Mihaljevic B,Milosevic I,Mirás F,Morawska M,Motta M,Munir T,Murru R,Nunes R,Olivieri J,Pavlovsky MA,Piskunova I,Popov VM,Quaglia FM,Quaresmini G,Reda G,Rigolin GM,Shrestha A,Šimkovic M,Smirnova S,Špacek M,Sportoletti P,Stanca O,Stavroyianni N,Te D,Tomic K,Tonino S,Trentin L,Van Der Spek E,van M,Varettoni M,Visentin A,Vitale C,Vukovic V,Wasik E,Wróbel T,Segundo LYS,Yassin M,Coscia M,Rambaldi A,Montserrat E,Foà R,Cuneo A,Carrier M,Ghia P,Stamatopoulos K. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. J. Hematol. Oncol. 2022. 15. (1):p. 116-116. IF:28,500. (1).
